Meritage Portfolio Management Lowers Holdings in Supernus Pharmaceuticals, Inc. $SUPN

Meritage Portfolio Management trimmed its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 32.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 41,021 shares of the specialty pharmaceutical company’s stock after selling 19,377 shares during the quarter. Meritage Portfolio Management owned approximately 0.07% of Supernus Pharmaceuticals worth $1,960,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in shares of Supernus Pharmaceuticals by 8.8% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 14,375 shares of the specialty pharmaceutical company’s stock worth $453,000 after acquiring an additional 1,161 shares during the last quarter. CWM LLC lifted its stake in Supernus Pharmaceuticals by 92.4% in the 2nd quarter. CWM LLC now owns 3,080 shares of the specialty pharmaceutical company’s stock worth $97,000 after purchasing an additional 1,479 shares in the last quarter. Castlekeep Investment Advisors LLC purchased a new stake in Supernus Pharmaceuticals in the 2nd quarter worth $1,263,000. Villanova Investment Management Co LLC boosted its holdings in shares of Supernus Pharmaceuticals by 167.1% during the 2nd quarter. Villanova Investment Management Co LLC now owns 52,324 shares of the specialty pharmaceutical company’s stock valued at $1,649,000 after purchasing an additional 32,737 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH grew its position in shares of Supernus Pharmaceuticals by 30.4% during the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 85,534 shares of the specialty pharmaceutical company’s stock valued at $2,696,000 after purchasing an additional 19,949 shares in the last quarter.

Insider Transactions at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 710 shares of the firm’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $44.44, for a total value of $31,552.40. Following the completion of the sale, the vice president owned 14,508 shares of the company’s stock, valued at $644,735.52. This trade represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Frank Mottola sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $50.41, for a total value of $1,008,200.00. Following the transaction, the senior vice president directly owned 15,496 shares in the company, valued at approximately $781,153.36. This represents a 56.34% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 8.80% of the company’s stock.

Wall Street Analyst Weigh In

SUPN has been the topic of several research reports. Wall Street Zen raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Piper Sandler upgraded shares of Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $40.00 to $65.00 in a research report on Thursday, October 9th. Zacks Research cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 8th. Bank of America assumed coverage on shares of Supernus Pharmaceuticals in a report on Wednesday, October 29th. They issued a “buy” rating and a $65.00 target price on the stock. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $61.60.

Supernus Pharmaceuticals Stock Down 3.0%

NASDAQ SUPN opened at $50.26 on Friday. Supernus Pharmaceuticals, Inc. has a 52 week low of $29.16 and a 52 week high of $57.65. The firm has a market capitalization of $2.88 billion, a price-to-earnings ratio of -147.82, a PEG ratio of 0.50 and a beta of 0.67. The company has a fifty day moving average of $47.88 and a two-hundred day moving average of $44.81.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 earnings per share for the quarter, missing the consensus estimate of $0.82 by ($0.36). Supernus Pharmaceuticals had a negative net margin of 2.81% and a positive return on equity of 11.51%. The firm had revenue of $170.00 million during the quarter, compared to analysts’ expectations of $175.82 million. During the same period in the prior year, the company posted $0.69 EPS. The company’s revenue was up 9.3% compared to the same quarter last year. Equities research analysts anticipate that Supernus Pharmaceuticals, Inc. will post 2.38 EPS for the current year.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.